Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zavegepant Dose-Ranging Trial for Acute Migraine
NCT03872453Phase 3Completed
- Sponsor
- Pfizer
- Start
- Mar 2019
- Primary completion
- Oct 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of zavegepant in migraine, sponsored by Pfizer. Primary endpoints: Percentage of Participants With Freedom From Pain at 2 Hours Post-dose and Percentage of Participants With Freedom From Most Bothersome Symptom (MBS) at 2 Hours Post-dose. Started Mar 2019; status: completed.
02
Drugs
zavegepant
03
Conditions
migraine
Beyond the preview
Go deeper on NCT03872453.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03872453.